Compare AIRG & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIRG | PMVP |
|---|---|---|
| Founded | 1995 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.3M | 76.8M |
| IPO Year | 2016 | 2020 |
| Metric | AIRG | PMVP |
|---|---|---|
| Price | $7.02 | $1.11 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $6.25 | N/A |
| AVG Volume (30 Days) | 96.1K | ★ 307.4K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.65 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $51,779,000.00 | N/A |
| Revenue This Year | $10.31 | N/A |
| Revenue Next Year | $20.71 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.00 | $0.96 |
| 52 Week High | $7.66 | $1.88 |
| Indicator | AIRG | PMVP |
|---|---|---|
| Relative Strength Index (RSI) | 51.91 | 36.92 |
| Support Level | $6.52 | $1.04 |
| Resistance Level | $7.52 | $1.26 |
| Average True Range (ATR) | 0.40 | 0.06 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 32.27 | 27.78 |
Airgain Incs a provider of advance wireless connectivity solutions. It is focused on delivering high-performance, cost-effective, and energy-efficient wireless solutions that enable rapid market deployment. It mission is to connect the world through integrated, and optimized wireless solutions. Companies' diverse product portfolio serves three primary markets: enterprise, automotive, and consumer. While historically recognized for high-performance radio frequency (RF) components, Airgain is increasingly delivering integrated, system-level connectivity solutions that combine hardware, software, and cloud management. The enterprise market demands reliable wireless access across diverse settings, including smart cities, campuses, stadiums, transportation hubs, utilities, buildings suburbs.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.